ReviewAmerican journal of clinical and experimental immunology2026
Antagonists of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) as rationale and therapeutic potential of combination cancer therapy.
Review in American journal of clinical and experimental immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-Derived Growth Factor (PDGF)/Platelet-Derived Growth Factor Receptor (PDGFR) are key regulators in the complex network of signaling from Receptor Tyrosine Kinases (RTKs). PDGFR has historically been considered an attractive therapeutic target given its association with oncogenic mutations, gene fusions and altered signaling. However, growing evidence suggests that PDGFR functions beyond these traditional roles as a single therapeutic target and into a broader role as a central coordinator of oncogenic signaling. PDGFR mediates cross-talk among multiple oncogenic pathways such as EGFR, VEGFR and IGF-1R thus supporting redundancy in oncogenic signaling, resistance to therapy and adaptive changes in tumors. The biologic effects of PDGFR signaling do not end at tumor cell borders but rather include the regulation of the tumor microenvironment. Specifically, PDGFR directs the recruitment of pericytes, remodeling of the extracellular matrix and influences interstitial fluid pressure (IFP); each effect ultimately impacts both drug delivery and therapeutic efficacy. Studies have demonstrated that inhibition of PDGFR reduces stromal tension and normalizes tumor vasculature resulting in enhanced penetration of chemotherapy, targeted and radiation therapy. As such, these studies provide rationale for using PDGFR directed strategies in order to enhance treatment outcome via rational combinations of drugs. This review aims to integrate current knowledge of PDGF/PDGFR biology based on molecular interactions, tumor microenvironment dynamics and therapeutic approaches. It will highlight how PDGFR directed therapeutic strategies may serve to circumvent drug resistance, enhance drug delivery, enable use of biomarkers to drive combination therapeutics and promote a systems-level understanding of PDGFR function as a basis for advancing its translational application in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.